13F Holdings
中文EN

ACAD ACADIA PHARMACEUTICALS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1070494 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY14.8%
TTM net income YoY38.7%
TTM EPS YoY36.8%
Revenue 3-yr CAGR23.9%
Net income 3-yr CAGR—

Margins

Gross margin90.5%
Operating margin10.2%
Net margin30.1%
FCF margin6.8%
EBITDA margin10.3%

Returns

ROE31.4%
ROA23.2%
ROIC (approx.)14.2%
Asset turnover0.77x

Leverage & solvency

Liabilities / assets22.7%
Debt / equity0.00x
Current ratio3.82x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.27x
Accruals ratio16.9%
Payout ratio—
Capex / revenue1.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$1.07B$957.80M$726.44M$517.24M$484.14M
Cost of revenue$89.00M$81.84M$41.64M$10.17M$19.14M
Gross profit$982.51M$875.96M$684.80M$507.07M$473.30M
R&D expense$328.80M$303.25M$351.62M$361.57M$239.41M
SG&A expense$548.89M$488.43M$406.56M$369.09M$396.03M
Operating income$104.81M$230.79M-$73.38M-$223.60M-$170.44M
Pretax income$138.90M$258.07M-$51.04M-$213.44M-$167.52M
Income tax-$252.10M$31.62M$10.25M$2.53M$351,000
Net income$391.00M$226.45M-$61.29M-$215.97M-$167.87M
EBITDA$105.68M$231.71M-$71.92M-$221.57M-$168.20M
EPS (basic)2.321.37-0.37-1.34-1.05
EPS (diluted)2.301.36-0.37-1.34-1.05
Weighted avg. shares (diluted)169.92M166.36M163.82M161.68M160,493
Balance sheet
Cash & equivalents$177.69M$319.59M$188.66M$114.85M$147.44M
Short-term investments$641.99M$436.40M$250.21M$301.98M$373.27M
Receivables$121.46M$98.74M$98.27M$62.20M$64.37M
Inventory$111.37M$91.69M$40.45M$11.56M$14.10M
Current assets$1.06B$938.32M$616.12M$507.94M$617.82M
PP&E, net$7.51M$4.21M$4.61M$6.02M$8.05M
Intangibles$108.89M$119.78M$65.49M$0$0
Total assets$1.56B$1.19B$748.96M$587.81M$700.12M
Current liabilities$277.11M$394.87M$254.25M$125.63M$96.07M
Total liabilities$336.81M$454.96M$317.20M$187.40M$159.23M
Shareholders' equity$1.23B$732.79M$431.75M$400.41M$540.89M
Shares outstanding170.31M166.71M164.65M162.06M161.01M
Cash flow statement
Operating cash flow$109.84M$157.72M$16.70M-$114.03M-$125.66M
Capital expenditure$4.69M$523,000$50,000$0$1.12M
Free cash flow$105.15M$157.20M$16.65M-$114.03M-$126.78M
Investing cash flow-$302.56M-$30.54M$32.00M$73.24M-$71.10M
Financing cash flow$49.88M$6.84M$25.13M$8.20M$18.16M
Depreciation & amortization$871,000$920,000$1.46M$2.03M$2.24M
Stock-based compensation$52.13M$67.05M$66.42M$68.20M$63.62M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.